Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
Chemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy. Netupitant/palonosetron (NEPA; Akynzeo®) is a fixed-dose combination of two drugs (netupitant, a neurokinin 1 receptor ant...
Saved in:
Main Authors: | A. G. Kedrova (Author), A. I. Berishvili (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
by: Helene Cawston, et al.
Published: (2017) -
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
by: Navari RM
Published: (2014) -
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
by: Lorusso V
Published: (2016) -
Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
by: Janicki PK
Published: (2016) -
Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
by: Zhou M, et al.
Published: (2015)